Lyell Immunopharma Inc. (Nasdaq: LYEL), a late-stage clinical company developing next-generation CAR T-cell therapies for cancer patients, is scheduled to participate in the Morgan Stanley 23rd Annual Global Healthcare Conference. The event will take place on Monday, September 8th, at 9:15 am Eastern Time. Members of Lyell's senior management team will present at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521320-en) on September 02, 2025, and is solely responsible for the information contained therein.